AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01775540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Ultra
Description: Artificial tear Eyedrop, 1 drop used QID for 4 weeks
Study NCT01775540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution,1 drop used QID for 4 weeks
Study NCT01775540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maxidex
Description: Eyedrop-1 drop QID for 4 weeks
Study NCT01938729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection and placement of hepatic artery infusion pump
Study NCT01938729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOXURIDINE
Study NCT01938729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEXAMETHASONE
Study NCT01938729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMCITABINE
Study NCT02320656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Longitudinal (3 stages of the disease)
Study NCT02320656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate
Description: Longitudinal (3 stages of the disease)
Study NCT02320656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Single biopsy (optional)
Study NCT02320656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buccal swab
Description: Single sampling.
Study NCT04490681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Fixed dose Ertugliflozin (5mg)
Study NCT04490681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group
Study NCT02109276 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spheric Sensar(R) 3-piece IOL
Description: Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
Study NCT02109276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspheric Tecnis(R) 3-piece IOL
Description: Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
Study NCT03848780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Study NCT01858727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: forced air warming group
Description: 30 minutes before the preoperative will use forced air warming
Study NCT01858727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: do not heating group
Study NCT03525509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone hydrochloride
Description: Epidural bolus of 4mg of preservative free methadone hydrochloride (4mL of 1mg/mL solution)
Study NCT03525509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Epidural bolus of 4mg of preservative free morphine sulfate (4mL of 1mg/mL solution)
Study NCT02349061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab IV
Description: Weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0.
Study NCT02349061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Infusion
Description: Placebo intravenously at Week 0.
Study NCT02349061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Placebo subcutaneously at Weeks 8 and 16.
Study NCT01138514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)
Description: Applied to the entire face twice daily for 10 weeks
Study NCT01138514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)
Description: Applied to the entire face twice daily for 10 weeks
Study NCT01138514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04268238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hygiene Guidance
Description: Two weeks before the start of the study, the volunteers will go through a wash out period, where they should only use oral care products donated by the researchers, which should be used until the end of the study. The oral hygiene kit will contain 1 toothbrush (Professional Lab Series, Colgate Palmolive), 1 toothpaste without desensitizing agent, but with fluorine (Elmex) and 1 dental floss (Colgate).
Study NCT04268238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sealant Application
Description: Permaseal (Ultradent) is an unloaded resin based on methacrylate and photopolymerizable. The teeth that will be sealed will be isolated. 35% phosphoric acid will be applied for 20 seconds and then it will be necessary to wash and dry the tooth surface. Apply a thin layer of PermaSeal for 5 seconds to the tooth surface and light curing for 20 seconds. After that, it is necessary to evaluate occlusion.
Study NCT04268238 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Level Laser Application
Description: Volunteers will receive irradiation with AsGaAl laser, wavelength of 780nm (Laser XT Therapy, DMC, São Carlos, SP) with fixed power of 100mW, density of energy of 35 J/cm2 (considering a spot size of 0.028cm2 of this equipment), the dose will be 1 J per point. Irradiation will be performed at a cervical, an apical point, and another point exactly on the injury, totaling a dose of 3J. Treatment should be performed in 3 sessions with an ideal 72-hour interval between them.
Study NCT00399087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine oral administration
Study NCT00399087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV administration
Study NCT00399087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral administration
Study NCT00016354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benzoylphenylurea
Study NCT03791879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal dexamedatomidine analgesia
Description: Technique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22-G short-beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament.~After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg.
Study NCT03201120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outdoor Sun Behavior
Description: Participants will provide informed consent and complete a short background questionnaire about usual sun exposure and protection behaviors and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a computer monitor, keyboard and mouse setup. Each participant will view messages with different emotional appeals related to outdoor sun exposure (seeking shade, covering up, using sunscreen, and multiple behaviors). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
Study NCT03201120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indoor Tanning Behavior
Description: Upon arrival, participants will provide informed consent and complete a short background questionnaire about usual indoor tanning, sun exposure and protection behaviors, and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a typical computer monitor, keyboard and mouse setup. Each participant will view messages with each type of target behavior (freedom, health risk, appearance)). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
Study NCT01564017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac depot
Description: Depot sterile suspension fpor subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 1: 0.25 SPT
Study NCT01564017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac depot
Description: Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 2: 0.5 SPT
Study NCT01564017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac depot
Description: Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 3: 1 SPT
Study NCT01564017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac depot
Description: depot sterile suspension for subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 4: 2 SPT
Study NCT01564017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac depot
Description: Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 5: 4 SPT
Study NCT01564017 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Allergovac depot
Description: Sterile suspension for subcutaneous injection.~Same number of administration as the active groups
Study NCT04487405 — intervention group
Intervention type: DEVICE
Intervention: OVAnex
Description: OVAnex is a multivarite index assay assessing ovarian cancer risk
Study NCT04561219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide 500mg three times a day for 5 days
Study NCT04561219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times a day for 5 days
Study NCT02873312 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: StimRouter
Description: The StimRouter System is a neuromodulation system consisting of the following components and accessories:~* An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead.~* An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories.~* A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories.
Study NCT02873312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimRouter
Description: The StimRouter System is a neuromodulation system consisting of the following components and accessories:~* An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead.~* An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories.~* A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories.
Study NCT01483248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conventional therapy plus MenSC transplantation
Description: patients will receive conventional treatment,such as antiviral drugs, lowering aminotransferase and jaundice medicine.~MenSCs transplantation: taken i.v., twice per week, at a dose of 1\*10E6 MSC/kg body for 2 weeks.
Study NCT01483248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy plus placebo treatment
Description: 25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
Study NCT02349061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab SC
Description: Ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40 and up to Week 104 in study extension (for eligible participants)
Study NCT00604019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Description: Dopamine 5-20 mcg/kg/min to pre-determined max of 20
Study NCT03314181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Infusion; Intravenous (IV), or Tablet; Oral
Study NCT03314181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Infusion; Intravenous (IV), or Tablet; Oral
Study NCT03314181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
Study NCT02573935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: p.o. clarithromycin 500 mg twice daily for 63 days
Study NCT03314181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
Study NCT03314181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral
Study NCT02573935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily for 63 days
Study NCT02573935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCD induction therapy
Description: Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)
Study NCT03314181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
Study NCT03314181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
Study NCT02136199 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active Implementation of ShareEBM Toolkit
Study NCT02136199 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Passive Dissemination of Share EBM
Study NCT04346264 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NO intervention planned due to the observational study design only a diagnostic testing
Description: Only a diagnostic test (serum blood and antibody measurement) is planned
Study NCT00604019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine 5-20 mcg/min, to a pre-determined max of 20
Study NCT03229044 — intervention group
Intervention type: GENETIC
Intervention: Tetranectin
Description: Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. The subjects were 33-51 y of age (mean = 43.6, SD = 6.2) with a BMI of 16-33 kg/m2 (mean = 21.5, SD = 4.5). Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma Tetranectin,triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. And the tetranectin mRNA and protein level was measure in adipose tissue
Study NCT01670656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)
Description: Either 700 or 900 mcg NOMAC and 300 mcg E2 intravaginal ring for two 28-day cycles
Study NCT01670656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel containing contraceptive vaginal ring (ENG-CVR)
Description: Either 100 or 125 mcg ENG and 300 mcg E2, intravaginally for two 28-day cycles
Study NCT01670656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match vaginal ring, intravaginally for two 28-day cycles
Study NCT01670656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)
Study NCT02949206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64179375
Description: During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.
Study NCT01670656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)
Study NCT01602926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgical technique - Chevron-type distal metatarsal osteotomy
Description: The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws. The internal fixation screws used in the conventional surgical technique do not require removal.
Study NCT02573935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VCD induction therapy
Description: Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)
Study NCT04639297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroVision® IONM
Description: Using NeuroVision® prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
Study NCT01602926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive surgical technique
Description: The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal (see figures) .The distal end of the Kirschner wire is left outside the skin where it is cut to length and covered. The Kirschner wire is removed after six weeks.
Study NCT04639297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hospital Based IONM
Description: Using hospital based IONM prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
Study NCT02065713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Prefilled syringe with golimumab 50mg (Simponi®) administrated subcutaneously, once monthly, for 24 weeks.
Study NCT02065713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity
Study NCT01602926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive surgical technique
Description: The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity.
Study NCT02065713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity
Study NCT02065713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The prefilled syringe with placebo will be administrated subcutaneously, once monthly, for 24 weeks.